Find the products and resources you are looking for!
Get in touch!
Our local employees are always happy to answer your questions. Highly trained and experienced teams in your country can provide quick, helpful, and comprehensive support.
Miltenyi Biotec distribution:
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
Cookie Settings
We use cookies in order to provide the best possible website experience for you. This includes cookies that are technically required to ensure a proper functioning of the website, as well as cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for displaying personalized content. You are free to choose the categories you would like to permit. Please note that depending on your settings, the full functionality of the website may no longer be available. Further information can be found in our Privacy Statement.
Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. |
A) Before magnetic separation | |
Identification of PDCs and HPCs | Identification of MDC2s |
Figure 1Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. | Figure 1Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. |
Discrimination between PTK7-expressing cell types | |
Figure 1Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. | |
B) Enriched PTK7 (CCK-4)+ cells | |
Identification of PDCs and HPCs | Identification of MDC2s |
Figure 1Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. | Figure 1Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. |
Discrimination between PTK7-expressing cell types | |
Figure 1Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. |
Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. |
A) Before magnetic separation | |
Identification of PDCs and HPCs | Identification of MDC2s |
Figure 1Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. | Figure 1Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. |
Discrimination between PTK7-expressing cell types | |
Figure 1Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. | |
B) Enriched PTK7 (CCK-4)+ cells | |
Identification of PDCs and HPCs | Identification of MDC2s |
Figure 1Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. | Figure 1Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. |
Discrimination between PTK7-expressing cell types | |
Figure 1Isolation of PTK7 (CCK-4) + cells from PBMCs using the Anti-PTK7 (CCK-4) MicroBead Kit and a MiniMACS™ Separator with MS Columns. Aliquots are fluorescently stained (A) before and (B) after magnetic separation with CD34-FITC, CD303 (BDCA-2)-PE and CD141 (BDCA-3)-APC for identification of hematopoietic stem cells (HPCs), plasmacytoid dendritic cells (PDCs), and type-2 myeloid dendritic cells (MDC2), respectively. Before and after separation, cells were gated on R1 (PDCs), R2 (HPCs), and R3 (MDC2s). Due to specific expression of CD303 (BDCA-2), CD141 (BDCA-3), and CD34 there is no overlap between the different PTK7-expressing cell types, and PDCs, HPCs, and MDC2s are clearly discriminated. |
Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.